论文部分内容阅读
目的通过观察成纤维细胞生长因子受体1(FGFR1)蛋白在肺鳞状细胞癌(SCCL)组织中的表达,探讨FGFR1阳性病例的临床病理特征以及免疫组织化学(IHC)方法在筛查肺鳞状细胞癌FGFR1阳性病例中的意义。方法应用组织芯片技术制备208例SCCL组织微阵列;应用IHC检测FGFR1蛋白表达,结果与临床病理参数比较分析。结果 208例SCCL患者中FGFR1阳性13例,阳性率为6.3%。FGFR1阳性组中肿瘤大于5cm患者比例明显高于FGFR1阴性组(P<0.05);淋巴结转移组FGFR1阳性率较无淋巴结转移组明显增高(9.7%比2.9%,P<0.05);Ⅲ、Ⅳ期患者FGFR1阳性率较Ⅰ、Ⅱ期患者明显增加(13.1%比1.6%,P<0.01)。吸烟患者较不吸烟患者FGFR1阳性率差异不明显(P>0.05),但随吸烟指数的增加,有增高的趋势。结论 FGFR1阳性表达与SCCL患者肿瘤体积较大、淋巴结转移以及临床分期较晚相关;与年龄、性别、肿瘤部位、分化程度及吸烟等无明显相关。
Objective To observe the expression of fibroblast growth factor receptor 1 (FGFR1) protein in lung squamous cell carcinoma (SCCL) and to investigate the clinicopathological features and immunohistochemistry (IHC) of FGFR1 positive cases in the screening of lung squamous cell carcinoma Significance of FGFR1-positive cases of cell carcinoma. Methods Tissue microarray technique was used to prepare 208 SCCL tissue microarrays. IHC was used to detect the expression of FGFR1 protein. The results were compared with clinicopathological parameters. Results FGFR1 positive in 208 cases of SCCL patients in 13 cases, the positive rate was 6.3%. The positive rate of FGFR1 in lymph node metastasis group was significantly higher than that in non-lymph node metastasis group (9.7% vs 2.9%, P <0.05); Stage Ⅲ and Ⅳ were higher in FGFR1 positive group than those in FGFR1 negative group (P <0.05) The positive rate of FGFR1 was significantly higher in patients with stage Ⅰ and Ⅱ (13.1% vs 1.6%, P <0.01). There was no significant difference in the positive rate of FGFR1 between smokers and non-smokers (P> 0.05), but there was an increasing trend with the increase of smoking index. Conclusion The positive expression of FGFR1 is correlated with the larger tumor volume, lymph node metastasis and clinical stage in patients with SCCL, but not with age, sex, tumor location, differentiation and smoking.